Results 61 to 70 of about 8,219 (198)

Therapeutic JAK Inhibition in Idiopathic Subglottic Stenosis

The Laryngoscope, EarlyView.
Three patients with idiopathic subglottic stenosis and rheumatoid arthritis began JAK inhibitor therapy, after which the mean surgical‐free interval between endoscopic dilations rose from 317 to 631 days and the annualized dilation rate fell from 1.24 to 0.38 per patient‐year. Figure 2 shows this as a per‐patient timeline.
Riley M. Larkin, Ioan Lina, Julianna Kostas, Caroline Christmann, Kevin Byram, Alexander Gelbard   +5 more
wiley   +1 more source

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient ...
Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein S. de Bruin-Weller, Sonja Ständer, Andrew E. Pink, Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg   +17 more
doaj   +1 more source

Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea

Frontiers in Immunology
IntroductionConventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitors upadacitinib and abrocitinib in the treatment of refractory rosacea has rarely
Ting Zhang, Xu Liu, Lu Zhang, Xian Jiang, Xian Jiang   +4 more
doaj   +1 more source

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

Clinical and Translational Science, 2022
Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA) and recently approved by the European Medicines Agency for the treatment of psoriatic arthritis (PsA).
Elena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, Jaclyn K. Anderson, Mohamed‐Eslam F. Mohamed   +4 more
doaj   +1 more source

Pregnancy in CTD‐interstitial lung disease: Current evidence, clinical challenges, and a proposed management algorithm

Rheumatology &Autoimmunity, EarlyView.
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina, Ghaydaa Aldabie, Mohammad Abdulsalam, Ali Jawad   +3 more
wiley   +1 more source

Upadacitinib-induced interstitial pneumonitis

Drug-induced lung injury represents a heterogeneous group of adverse reactions, with an increasing number of implicated medications each year. We report a case of pneumonitis in a woman recently commenced on upadacitinib for ulcerative colitis.
Maninder Pal Singh, Natasha Marcella Vaselli, Pradeep Kakkadasam Ramaswamy   +2 more
core   +1 more source

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

, 2022
BACKGROUND: Primary (week 16) results from the ongoing phase 3, double-blind AD Up study (NCT03568318) demonstrate a positive benefit-risk profile for upadacitinib + topical corticosteroid (TCS) in patients with moderate-to-severe atopic dermatitis ...
de Bruin-Weller, Marjolein, Silverberg, Jonathan I, Reich, Kristian, Bieber, Thomas, Soong, Weily, Rosmarin, David, Zeng, Jiewei, Costanzo, Antonio, Chu, Alvina D, Lynde, Charles, Liu, John, Kabashima, Kenji, Ladizinski, Barry, Gamelli, Amy   +13 more
core   +1 more source

Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease [PDF]

, 2020
Background & Aims: We evaluated the efficacy and safety of upadacitinib, an oral selective Janus kinase 1 inhibitor, in a randomized trial of patients with Crohn’s disease (CD).Methods: We performed a double-blind, phase 2 trial in adults with ...
Ghosh, Subrata, Pangan, Aileen L., Thakkar, Roopal B., Thakkar, Roshni, Feagan, Brian G., Scherl, Ellen, Lewis, James D., D'Haens, Geert, Herfarth, Hans, Colombel, Jean-frederic, Vitale, Lauren, Mohamed, Mohamed-eslam F., Lacerda, Ana P., Schreiber, Stefan, Othman, Ahmed A., Sandborn, William J., Zhou, Qian, Loftus, Edward V., Van Assche, Gert, Panes, Julian, Armuzzi, Alessandro, Huang, Bidan, Peyrin-biroulet, Laurent, D’haens, Geert   +23 more
core   +1 more source

Benzalkonium Chloride in Eye Drops Causing Allergic Contact Dermatitis: A Case Series

Australasian Journal of Dermatology, EarlyView.
ABSTRACT We present three patients who developed allergic contact dermatitis (ACD) from benzalkonium chloride (BAK) in ophthalmic drops. BAK is a preservative commonly found in ophthalmic formulations and there is a rising trend of ACD to this allergen. The irritant and sensitising properties of BAK on the ocular mucosa will be discussed.
Arav Kannen, Penelope Harrison, Elizabeth Christou   +2 more
wiley   +1 more source

Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis

Inflammatory Intestinal Diseases
Introduction: Upadacitinib and tofacitinib, oral Janus kinase inhibitors, have demonstrated efficacy and safety in ulcerative colitis (UC) in clinical trials. However, real-world comparative data are limited.
Tareq Alsaleh, Abdul Mohammed, Aimen Farooq, Magda Elamin, Amr Akl, Karim Mohamed Yassin, Ahmed Elnaggar, Jennifer Seminerio   +7 more
doaj   +1 more source